What is cholangiocarcinoma?

Cholangiocarcinoma is a cancer that starts in the bile ducts (the tubes that carry bile from the liver to the small intestine). It is uncommon but its incidence has been rising. It is divided by location into three types: intrahepatic (within the liver), perihilar (at the junction of the right and left bile ducts as they leave the liver), and distal (in the part of the bile duct closer to the small intestine). Each type has somewhat different presentation and management.

The diagnostic pathway. Cholangiocarcinoma often presents with painless jaundice (yellow skin and eyes from a blocked bile duct), itching, weight loss, and abnormal liver tests. Diagnosis usually involves imaging (CT, MRI, MRCP), endoscopic procedures (ERCP for cytology and brush samples), and sometimes percutaneous biopsy. Comprehensive molecular profiling of the tumour tissue is now an essential step in advanced disease.

Why molecular profiling matters so much. Until recently, cholangiocarcinoma was treated with chemotherapy alone, with poor outcomes. Modern molecular profiling identifies specific genetic alterations in many cholangiocarcinomas that have targeted therapies available.

FGFR2 fusions: occur in roughly 10 to 15 percent of intrahepatic cholangiocarcinomas. Several oral medicines (pemigatinib, infigratinib, futibatinib) are approved for this molecular subset.

IDH1 mutations: occur in roughly 15 to 20 percent of intrahepatic cholangiocarcinomas. Ivosidenib is approved for this molecular subset.

HER2 amplification: occurs in a subset of biliary tract cancers, particularly gallbladder cancer. Trastuzumab deruxtecan and zanidatamab are options.

Other actionable alterations: BRAF V600E mutations (dabrafenib plus trametinib), NTRK fusions (larotrectinib, entrectinib), MSI-high status (immunotherapy), KRAS G12C mutations (programs in trials).

The therapy approach.

Resectable disease: surgical resection offers the only chance of cure. Capecitabine chemotherapy after surgery improves outcomes.

Advanced disease: the modern first-line is the chemotherapy combination of gemcitabine plus cisplatin combined with an immune-therapy medicine (durvalumab or pembrolizumab). Comprehensive molecular profiling identifies whether targeted therapy is available, either now or after first-line chemotherapy plus immunotherapy.

The research direction. The cholangiocarcinoma trial landscape is increasingly active. Late-stage programs include FGFR2 follow-on medicines, second-generation IDH inhibitors, combination strategies, and additional targeted therapy for less common molecular alterations.

What to expect. Cholangiocarcinoma remains a serious diagnosis but is no longer the chemotherapy-only category it was. Comprehensive molecular profiling at diagnosis, treatment at a centre with expertise in biliary tract cancers, and consideration of clinical trials when appropriate are the most important things that improve outcomes.